ElevateBio Announces $401 Million Series D Financing to Further Accelerate Growth

Posted by ISPE Boston
On June 1, 2023

ElevateBio, LLC (ElevateBio), a technology-driven company focused on powering the creation of life-transforming cell and gene therapies, announced the closing of its $401 million Series D financing led by the AyurMaya Capital Management Fund, managed by Matrix Capital Management, and joined by a leading group of new and existing investors. ElevateBio’s syndicate now includes new […]

Novo Nordisk and Life Edit Therapeutics Establish Multi-Target Collaboration

Posted by ISPE Boston
On June 1, 2023

Novo Nordisk and Life Edit Therapeutics, Inc., an ElevateBio company focused on next-generation gene editing technologies and therapeutics, today announced a research and development collaboration to discover and develop gene editing therapies against a select set of therapeutic targets. With a focus on advancing base editing capabilities, Novo Nordisk will leverage Life Edit’s suite of […]

Congratulations to our Spring Membership Promo Winners

Posted by ISPE Boston
On May 31, 2023

Please join us in welcoming our new members! Our Spring Membership Drive has concluded and we’d like to congratulate the first twenty-five that registered! They have won an ISPE beach towel AND an ISPE stainless-steel wine mug. They’re perfect for these rising temperatures and days at the beach! Our members receive special pricing for chapter […]

Spring Golf at Blue Hills!

Posted by ISPE Boston
On May 23, 2023

At the 2023 ISPE Spring Golf Tournament, the attendees were greeted with the stunning visuals of Blue Hill Country Club’s vast grounds. After some networking and picking up their swag bags full of branded swag from Avision Young, DPS, Haworth, Kneat Solutions, NECI, Sequence and WB Engineers at registration, the golfers set out on their […]

Eli Lilly Alzheimer’s Drug Shows Promise in Phase 3 Study

Posted by ISPE Boston
On May 18, 2023

Eli Lilly has announced positive results of its Phase 3 study, showing that donanemab significantly slowed cognitive and functional decline in people with early symptomatic Alzheimer’s disease. Based on these results, Lilly will proceed with global regulatory submissions as quickly as possible and anticipates making a submission to the FDA this quarter. Lilly will work with the FDA and […]

Convergent Raises $90 Million for Prostate Cancer Drug

Posted by ISPE Boston
On May 18, 2023

Cambridge-based Convergent Therapeutics has completed a $90 million Series A financing that will support development of a pipeline of novel radioantibodies, including its lead program with CONV01-α for the treatment of advanced prostate cancer. Convergent is a clinical-stage biotech focused on developing next-generation radiopharmaceutical therapies for prostate and other cancers. “While considerable progress has been made in […]

Sarepta Gene Therapy Gets Nod from FDA Advisory Committee

Posted by ISPE Boston
On May 18, 2023

Sarepta Therapeutics has announced that the FDA Cellular, Tissue and Gene Therapies Advisory Committee (CTGTAC) voted 8 to 6 in support of accelerated approval of SRP-9001, a gene transfer therapy for treatment of patients with a form of Duchenne muscular dystrophy (DMD). The committee’s vote, while not binding, will be considered by the FDA when making its decision […]

Upcoming Webinar: Challenges and Solutions for GxPs in Cell/Gene Therapy Product Development, June 3rd 4-6PM

Posted by ISPE Boston
On May 18, 2023

Framingham State University and MassBay Community College are presenting a panel discussion with leaders from the New England Regional Chapter Society of Quality Assurance to discuss the current challenges and solutions for various Good Practices (GxPs) in the Cell/Gene Therapy industry, on June 3rd (Saturday) from 4 to 6 pm EST. The event will be […]

FDA Approves Seres Microbiota-Based Drug

Posted by ISPE Boston
On May 4, 2023

Cambridge-based Seres Therapeutics and Nestlé Health Science have announced FDA approval of Vowst, an orally administered microbiota-based therapeutic to prevent recurrence of C. difficile Infection (CDI) in adults following antibacterial treatment for recurrent CDI (rCDI). Vowst was previously granted Breakthrough Therapy and Orphan Drug Designations by the FDA. Recurrent CDI represents significant unmet need and is a leading cause […]

Orbital Raises $270 Million in First Funding Round

Posted by ISPE Boston
On May 4, 2023

RNA medicines developer Orbital Therapeutics has announced the successful closing of $270 million Series A financing. Orbital Therapeutics is focused on expanding the applicability of RNA-based medicines across a range of human diseases, including in the areas of next-generation vaccines, immunomodulation, and protein replacement. “Few companies can possess the know-how, technology and biologic insights to […]

Page 22 of 118«‹20 212223 24 ›»